[Lipid profile in patients with Cancer before and after receiving Xeloda]
Medical Journal of Tabriz University of Medical Sciences and Health Services. 2015; 37 (3): 12-17
em Persa
| IMEMR
| ID: emr-173984
ABSTRACT
Background and Objectives:
Capecitabine [Xeloda] is an orally administered pro-drug of 5-fluorouracil, which is used as chemotherapeutic agent. Some studies have raised concerns about the lipid profile changes following Xeloda. In this study we examined such probable changes in patients before and after receiving Xeloda
Buscar no Google
Índice:
IMEMR (Mediterrâneo Oriental)
Assunto principal:
Hipertrigliceridemia
/
Capecitabina
/
Neoplasias Gastrointestinais
/
Hipercolesterolemia
/
Neoplasias
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Persa
Revista:
Med. J. Tabriz Univ. Med. Sci. Health Serv.
Ano de publicação:
2015
Similares
MEDLINE
...
LILACS
LIS